1Baltina LA. Chemical modification of glycyrrhizic acid as a route to new bioactive compounds for medicine. Curr Med Chem, 2003, 10 (2): 155-171.
2Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T ceils. Immunity, 2002, 17 (5): 629-638.
3Ekstrtǒm GM. Oxazolone-induced colitis in rats: effects of budesonide, cyclosporin A, and 5-aminosalicylic acid. Scand J Gastroenterol, 1998, 33 (2): 174-179.
4Boirivant M, Fuss IJ, Ferroni L, et al. Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis. J Immunol, 2001, 166 (5): 3522-3532.
5Andresen L, Jcrgensen VL, Perner A, et al. Activation of nuclear factor kappaB in colonic mucosa from patients ~ith collagenous .and ulcerative colitis. Gut, 2005, 54 (4): 503-509.
6Suzuki A, Hanada T, Mitsuyama K, et al. CIS3/SOCS3/ SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med, 2001, 193 (4): 471-481.
